58,453 Shares in IQVIA Holdings Inc. $IQV Acquired by Cibc World Market Inc.

Cibc World Market Inc. bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 58,453 shares of the medical research company’s stock, valued at approximately $11,294,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Korea Investment CORP purchased a new position in IQVIA in the 2nd quarter valued at about $13,918,000. BlackRock Inc. acquired a new position in shares of IQVIA in the 2nd quarter valued at about $2,811,292,000. Concurrent Investment Advisors LLC boosted its stake in IQVIA by 36.0% in the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after acquiring an additional 3,161 shares during the period. Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth about $976,000. Finally, Nippon Life Global Investors Americas Inc. boosted its position in IQVIA by 36.6% during the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock worth $17,898,000 after acquiring an additional 21,270 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.2%

NYSE IQV opened at $260.30 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock’s 50 day moving average is $214.97 and its two-hundred day moving average is $187.62. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $261.88. The company has a market capitalization of $42.85 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period last year, the business earned $2.81 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. HSBC reaffirmed a “buy” rating and set a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. Mizuho boosted their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.